Isotretinoin Pregnancy and Breastfeeding Warnings
Isotretinoin Pregnancy Warnings
Isotretinoin has been assigned to pregnancy category X by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy; however, isotretinoin is known to be teratogenic to humans. The birth defects documented following exposure to isotretinoin include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Isotretinoin use is considered contraindicated during pregnancy.
Isotretinoin must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking isotretinoin in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. The birth defects documented following exposure to isotretinoin include abnormalities of the face, eyes, ears, skull, central nervous system (CNS), cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported. External abnormalities have included skull abnormality, ear abnormalities, eye abnormalities (including microphthalmia), facial dysmorphia, and cleft palate. Internal abnormalities have included CNS abnormalities, cardiovascular abnormalities, thymus gland abnormality, and parathyroid hormone deficiency. In some cases death has occurred with some of the abnormalities previously mentioned. If pregnancy occurs during the course of treatment of a female, the drug must be discontinued immediately and she should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling. In an FDA Public Health Advisory, the FDA announced the approval of the Strengthened Risk Management Program for Isotretinoin. Because of the high teratogenicity of isotretinoin and to minimize fetal exposure, isotretinoin is available only through a special restricted distribution program called iPLEDGE (TM). Prescribers, pharmacies, and wholesalers must be registered and activated with the iPLEDGE program in order to prescribe, dispense, or distribute isotretinoin. Isotretinoin must only be dispensed to patients who are registered and meet all the requirements of iPLEDGE. This registration process ensures that prescribers, pharmacists, and patients agree to assume specific responsibilities to ensure that patients do not become pregnant while taking isotretinoin and do not get prescribed the medicine if they are pregnant. Further details on iPLEDGE are available at www.ipledgeprogram.com. Isotretinoin was first marketed in the US in September of 1982. In July of 1983, the first reports of malformed infants were received by the manufacturer prompting a "Dear Doctor" letter reiterating the dangers of isotretinoin use in pregnancy. Despite further educational efforts by the manufacturer, unintentional exposures of pregnant women to isotretinoin continue to occur. Cardiovascular abnormalities observed have included interrupted aortic arch, ventricular septal defect, atrial septal defect, transposition of the great vessels, and Tetralogy of Fallot. Ear abnormalities have included anotia, micropinna, and small or absent external auditory canals. Central nervous system abnormalities have included cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, and cranial nerve deficit. Craniofacial abnormalities have frequently included occipital vaulting, and/or a sharply sloping, narrow forehead, wide-spaced eyes, small chin, and flat, depressed nasal bridge. Dai et al. 1992 reported 433 first-trimester exposures to isotretinoin of which pregnancy outcomes was known in 409 cases. Elective abortion was performed in 222 (54%) of these pregnancies and 29 (7%) ended in spontaneous abortions. Of 151 births, 72 (48%) were normal and 71 (47%) had congenital malformations. Malformations and spontaneous abortions occurred in women whose exposure to isotretinoin had been less than one week. Limb reduction defects have been reported in at least two infants, along with other multiple malformations characteristic to isotretinoin exposure. One infant with isotretinoin embryopathy, including thymic hypoplasia, demonstrated progressive attrition of T cells following her birth. She died after several bouts with pneumonia. It is suggested that isotretinoin may provide insult to the immune system as well as other teratogenic effects. Another infant with isotretinoin embryopathy and bilateral major ear deformities also demonstrated significant bilateral conductive hearing loss and left sided sensorineural loss. Peripheral and central vestibular dysfunction was also present. Any suspected fetal exposure during or 1 month after isotretinoin therapy must be reported at once to the FDA via the MedWatch number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the Internet (www.ipledgeprogram.com).
Isotretinoin Breastfeeding Warnings
There are no data on the excretion of isotretinoin into human milk. Because of the potential for adverse effects in nursing infants, breast-feeding is considered contraindicated by the manufacturer.
References for pregnancy information
- Stern RS, Rosa F, Baum C "Isotretinoin and pregnancy." J Am Acad Dermatol 10 (1984): 851-4
- Chan A, Hanna M, Abbott M, Keane RJ "Oral retinoids and pregnancy." Med J Aust 165 (1996): 164-7
- de la Cruz E, Sun S, Vangvanichyakorn K, Desposito F "Multiple congenital malformations associated with maternal isotretinoin therapy." Pediatrics 74 (1984): 428-30
- Koren G, Pastuszak A, Ito S "Drugs in pregnancy." N Engl J Med 338 (1998): 1128-37
- Rizzo R, Lammer EJ, Parano E, Pavone L, Argyle JC "Limb reduction defects in humans associated with prenatal isotretinoin exposure." Teratology 44 (1991): 599-604
- "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
- Westerman ST, Gilbert LM, Schondel L "Vestibular dysfunction in a child with embryonic exposure to accutane." Am J Otol 15 (1994): 400-3
- McBride WG "Limb reduction deformities in child exposed to isotretinoin in utero on gestation days 26-40 only." Lancet 1 (1985): 1276
- Atanackovic G, Koren G "Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program." Can Med Assn J 160 (1999): 1719-20
- Benke PJ "The isotretinoin teratogen syndrome." JAMA 251 (1984): 3267-9
- Fernhoff PM, Lammer EJ "Craniofacial features of isotretinoin embryopathy." J Pediatr 105 (1984): 595-7
- Coberly S, Lammer E, Alashari M "Retinoic acid embryopathy: case report and review of literature." Pediatr Pathol Lab Med 16 (1996): 823-36
- CDC "Isotretinoin--a newly recognized human teratogen." MMWR Morb Mortal Wkly Rep 33 (1984): 171-3
- CDC "Birth defects caused by isotretinoin--Neew Jersey." JAMA 259 (1988): 2362, 2365
- Guirgis MF, Wong AM, Tychsen L "Clinicopathologic reports, case reports, and small case series: congenital restrictive external ophthalmoplegia and gustatory epiphora associated with fetal isotretinoin toxicity." Arch Ophthalmol 120 (2002): 1094-5
- Lott IT, Bocian M, Pribram HW, Leitner M "Fetal hydrocephalus and ear anomalies associated with maternal use of isotretinoin." J Pediatr 105 (1984): 597-600
- Rappaport EB, Knapp M "Isotretinoin embryopathy--a continuing problem." J Clin Pharmacol 29 (1989): 463-5
- Dai WS, LaBraico JM, Stern RS "Epidemiology of isotretinoin exposure during pregnancy." J Am Acad Dermatol 26 (1992): 599-606
- Cohen M, Rubinstein A, Li JK, Nathenson G "Thymic hypoplasia associated with isotretinoin embryopathy." Am J Dis Child 141 (1987): 263-6
- Thomson EJ, Cordero JF "The new teratogens: accutane and other vitamin-A analogs." MCN Am J Matern Child Nurs 14 (1989): 244-8
References for breastfeeding information
- "Product Information. Accutane (isotretinoin)." Roche Laboratories, Nutley, NJ.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.